Tag: Beti-cel

Cell and Gene Therapy, Industry, News

Bluebird bio’s beta-thalassaemia gene therapy rejected by NICE

February 12, 2021

Via: Pharma Times

Beti-cel, marketed as Zynteglo in Europe, is a gene therapy intended for the treatment of transfusion-dependent beta-thalassaemia (TDT) in people aged 12 years and older who do not have a beta0/beta0 genotype. It is indicated for TDT patients when haematopoietic […]